Sanyo Chemical


## Introduction

Extracellular vesicles (EVs), which are secreted by nearly all living cells and play crucial roles in various physiological processes, have attracted increasing attention from researchers. Numerous protocols for EV isolation such as ultracentrifugation and polymer precipitation have been developed, yet conventional methods each possess distinct strengths and limitations.

Here, we present a novel EV isolation technique, termed Hydrogel Adsorption Separation (HAS). This method selectively isolates EV particles with high purity through adsorption onto a hydrogel surface. EVs obtained from various biofluids using the HAS method have been successfully applied to multiple analytical techniques, including proteomics and flow cytometry, demonstrating its potential for both basic and clinical EV research.


## Material Design for EV Isolation Using Hydrogel Adsorption Separation (HAS)

#### Hydrogel: Cross-linked Polyacrylate




- Negative Surface Potential: Minimizes non-specific binding of impurities (e.g. albumin).
- High and Rapid Water Absorbance: Facilitates rapid sample concentration and separation.
- High Biocompatibility: Minimal interference with biomacromolecules.

#### EV Adsorption: Lipid bilayer anchoring by palmitoyl group




- EV membrane incorporation via long alkyl chain
- Reversible interactions with the hydrogel

#### **HAS Method Protocol**



### Results

## Adsorption and Elution of EV Model Substrate by HAS




Adsorption and dissociation of EV model substrate, liposome, were confirmed through fluorescence imaging and by quantifying the liposome recovery in each solution during the adsorption and elution processes.

## **EV Isolation using HAS and other methods**

EV isolation was performed using hydrogel adsorption separation (HAS), ultracentrifugation (UC), polymer precipitation (PP), and Tim4-affinity (Tim4) to evaluate their distinct features.

## EV yield and purity

EV isolation from urine samples of chronic kidney disease (CKD) patients was conducted to compare recovery yield and purity.






Figure. EV purities of EV solutions isolated using four different methods. Purity was calculated using the equation below. Purity = (CD9+CD63+ EV [pg])/(Total Protein [µg]) Sample: Urine from CKD patients

HAS

Tim4

proteins across EV solutions.

Data: Provided by Nippon Becton Dickinson Company, Ltd.

Figure. Correlation heatmap of identified

Sample: Provided by Tokushima Univ.

Data: Provided by APRO Science Group /

0.55

1.00

UC

Pharma Foods International Co., Ltd

**Figure.** SDS-PAGE with subsequent silver staining (upper) and Western blot analysis (lower) of EV solutions. Sample: Urine from a CKD patient (CKD1)

Tim4

Non-EV Proteins

CD9

300

**Proteomics** 


by UC, Tim4, and HAS.


HAS method showed high EV recovery yield and purity.


EV proteins subset


## **EV** isolation by HAS















0.1mL (human serum, plasma)


Sample volume: 1mL (urine, conditioned medium)

Figure. Size distributions of recovered EV solution from various biofluids.

Small EVs (sEVs, <200 nm) exhibiting sharp size distributions were observed.

## <|mmunoassay of EV markers>





**Conditions** ELISA: CD9/CD63 Exosome ELISA kit (Cosmo Bio) Western blot: anti-CD9 (clone: 12A12, Cosmo Bio) anti-CD81 (clone: 12C4, Cosmo Bio)

EV markers (CD9, CD63, CD81) were detected in each EV solution.

## Flow Cytometry

proteins, orange: Non-EV proteins)

Figure. Numbers of identified proteins in EV

solutions with each isolation method (blue: EV

EVs from mouse serum, isolated by UC and HAS, were analyzed by flow cytometry using EV-specific markers (CD9, CD81), and nucleic acids in EV (SYBR Gold).

Serum EVs isolated using the HAS method yielded the highest number of protein identifications.

Figure. Venn diagrams showing the complete set of


detected proteins (left) and the EV protein subset (right).

Shotgun LC-MS/MS-based proteomic analyses were performed on human serum EV solutions isolated

Total proteins

CD9+CD81 CD9<sup>-</sup>CD81<sup>+</sup> CD9-CD81-CD9+CD81+ 43.6% 30.4% 13.5% 12.5%

23.9%




The CD9<sup>+</sup>CD81<sup>+</sup> EV subpopulation exhibited the SYBR Gold signal, indicating the presence of nucleic acids within the EVs (HAS, UC).

61.6%

Serum EVs isolated using the HAS method exhibited higher tetraspanin-positive EVs ratio than those isolated by UC.

#### <RNA isolation & detection>



RT-qPCR miR-15a Figure. RT-qPCR of miRNAs isolated

from urine EVs and HEK293 cell EVs.

RNA Isolation: Exosomal RNA Isolation kit (Norgen) Quantification: QuantiFluor RNA System (Promega) RT-PCR: TagMan assay (Thermofisher Scientific) Detection: QuantStudio 5 (Thermofisher Scientific)

**EV-specific miRNAs were detected in** EV solutions using RT-qPCR.

# EV solutions (Urine EVs, HEK293 cell

Discussion

#### EV isolation using HAS was compared with UC and other commercially available isolation kits (PP, Tim4).

	UC	PP	Tim4	HAS
Recovery yield	+	++	++	+++
Purity	+	+	+++	++
Total around time	3 h	2.5 h	2 h	1 h
Immunoassay	+	+	+	+
Nucleic acids	NM	NM	NM	+
Proteomics	+	NM	++	++
Flow cytometry	+	NM	NM	+
NM: Not-measured				

### Other Benefit for HAS method

- Simple protocol for EV isolation Purification completes in 3 step procedures.
- Non-specific molecular target for isolation Isolation of plant EV and bacterial EV is possible.

# Conclusion

(lower panels).

- We developed a novel EV isolation system that employs a hydrogel as an EV adsorption material.
- Purified EV solutions obtained via the HAS method exhibit a sharp size distribution ranging from 50 to 200 nm (sEV).
- The HAS method achieves high EV yield and purity, and the resulting EV solutions are suitable for downstream applications such as proteomics, transcriptomics, and single-vesicle analysis by flow cytometry.



The EV isolation kit, "EXORPTION™", which utilizes the HAS method, is currently available in Japan and will be launched in the U.S. starting in 2025.